智通财经APP获悉，香港联交所最新资料显示，1月20日，透云生物(01332)股东将股票由梧桐证券转入凯基证券亚洲，转仓市值3535.25万港元，占比5.04%。
透云生物此前发布截至2025年6月30日止6个月中期业绩，该集团取得销售所提供货品及服务的收入3658.1万港元，同比减少20.82%；公司拥有人应占溢利1124.3万港元，去年同期则取得亏损4796.9万港元；每股盈利0.4港仙。
智通财经APP获悉，香港联交所最新资料显示，1月20日，透云生物(01332)股东将股票由梧桐证券转入凯基证券亚洲，转仓市值3535.25万港元，占比5.04%。
透云生物此前发布截至2025年6月30日止6个月中期业绩，该集团取得销售所提供货品及服务的收入3658.1万港元，同比减少20.82%；公司拥有人应占溢利1124.3万港元，去年同期则取得亏损4796.9万港元；每股盈利0.4港仙。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.